Safety and Tolerability of Single and Repeated Doses of ODM-203: An Open-label, Non-randomised, Uncontrolled, Dose Escalation, Multicentre, First-in-Human Study in Subjects With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs ODM 203 (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man
- Acronyms KIDES; KIDES-203
- Sponsors Orion
- 15 May 2019 Status changed from active, no longer recruiting to completed.
- 13 May 2019 Planned End Date changed from 1 Jan 2019 to 1 Jul 2019.
- 13 May 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History